{"preliminary_commentary":{"by_channel":{"youtube":1,"podcast":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tagraxofusp","venetoclax","azacitidine"]],"indication":"previously untreated CD123+ acute myeloid leukemia","name":"TRILLIUM","nct_id":"NCT06456463","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trillium-nct06456463. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TRILLIUM","arms":[{"description":"Participants will receive tagraxofusp in combination with venetoclax and azacitidine.","label":"Part 1 - Tagraxofusp (9 μg/kg/day)","type":"EXPERIMENTAL"},{"description":"Participants will receive tagraxofusp in combination with venetoclax and azacitidine.","label":"Part 1 - Tagraxofusp (12 μg/kg/day)","type":"EXPERIMENTAL"},{"description":"Participants (TP53 wild type) will receive tagraxofusp in combination with venetoclax and azacitidine.","label":"Part 2 - Tagraxofusp (Selected Dose) and TP53 Wild Type","type":"EXPERIMENTAL"},{"description":"Participants (TP53 mutated) will receive tagraxofusp in combination with venetoclax and azacitidine.","label":"Part 2 - Tagraxofusp (Selected Dose) and TP53 Mutated","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-02-11","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia"],"enrollment":{"count":85,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tagraxofusp","otherNames":["Tag","Elzonris"],"type":"DRUG"},{"name":"Venetoclax","otherNames":["Ven","Venclexta"],"type":"DRUG"},{"name":"Azacitidine","otherNames":["Aza","Vidaza"],"type":"DRUG"}],"last_update":"2026-08-06","lead_sponsor":"Stemline Therapeutics, Inc.","official_title":"A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-02-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Determination of Part 2 Selected Dose of Tagraxofusp When Administered in Combination with Venetoclax and Azacitidine","timeFrame":"Cycles 1-4 (up to 112 days; 28 days/cycle)"},{"measure":"Part 2: Number of Participants Achieving a Best Overall Response (BOR) of Complete Remission (CR)","timeFrame":"Cycles 1-4 (up to 112 days; 28 days/cycle)"}],"references":[],"start_date":{"date":"2025-01-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","url":"https://clinicaltrials.gov/study/NCT06456463"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trillium-nct06456463"}